Full text is available at the source.
Abstract
This meta-analysis evaluated the efficacy and safety of oral small-molecule glucagon-like peptide-1 receptor agonists (GLP-1RAs) in type 2 diabetes and obesity.
- Efficacy of GLP-1RAs in managing blood sugar levels in type 2 diabetes may be supported by aggregated data.
- Oral GLP-1RAs could be associated with weight loss in individuals with obesity.
- Safety profiles for these medications are assessed, indicating potential side effects.
- The analysis includes results from multiple studies, enhancing the reliability of findings.
Simplified